Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

MLA

Mills, Anthony M., et al. “Switch to Fixed-Dose Doravirine (100 Mg) with Islatravir (0·75 Mg) Once Daily in Virologically Suppressed Adults with HIV-1 on Bictegravir, Emtricitabine, and Tenofovir Alafenamide: 48-Week Results of a Phase 3, Randomised, Controlled, Double-Blind, Non-Inferiority Trial.” The Lancet. HIV, vol. 11, no. 6, June 2024, pp. e357–68. EBSCOhost, https://doi.org/10.1016/S2352-3018(24)00030-4.

APA

Mills, A. M., Rizzardini, G., Ramgopal, M. N., Osiyemi, O. O., Bogner, J. R., Hagins, D. P., Paredes, R., Reynes, J., Rockstroh, J. K., Carr, A., Su, F.-H., Klopfer, S. O., Eves, K., Plank, R. M., Correll, T., & Fox, M. C. (2024). Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial. The Lancet. HIV, 11(6), e357–e368. https://doi.org/10.1016/S2352-3018(24)00030-4

Chicago

Mills, Anthony M, Giuliano Rizzardini, Moti N Ramgopal, Olayemi O Osiyemi, Johannes R Bogner, Debbie P Hagins, Roger Paredes, et al. 2024. “Switch to Fixed-Dose Doravirine (100 Mg) with Islatravir (0·75 Mg) Once Daily in Virologically Suppressed Adults with HIV-1 on Bictegravir, Emtricitabine, and Tenofovir Alafenamide: 48-Week Results of a Phase 3, Randomised, Controlled, Double-Blind, Non-Inferiority Trial.” The Lancet. HIV 11 (6): e357–68. doi:10.1016/S2352-3018(24)00030-4.